Krebs Biochemicals submits SEBI compliance certificate for Q3 FY26
Krebs Biochemicals and Industries Limited submitted a certificate under SEBI regulations for the quarter ended December 31, 2025. The company's Registrar and Share Transfer Agent, KFIN Technologies Limited, confirmed that details of securities dematerialization/rematerialization have been furnished to stock exchanges.
This is a standard regulatory filing and does not introduce any new material information that would significantly affect the company's operations or stock price.
The announcement is a routine compliance filing and does not contain any new financial information or strategic developments that would impact the company's outlook.
Krebs Biochemicals and Industries Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025. The certificate, received from KFIN Technologies Limited, the company's Registrar and Share Transfer Agent, confirms that the details of securities dematerialized/rematerialized during the said period have been furnished to all the stock exchanges where the company's shares are listed.
The company has informed both BSE Limited and the National Stock Exchange of India Ltd about this submission. The certificate is a routine compliance filing related to the company's shareholding and depository operations.
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.